Phase 1 × Completed × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Clear all Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Phase 1 Completed
3 enrolled
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Phase 1 Completed
32 enrolled
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
Phase 1 Completed
66 enrolled
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Phase 1 Completed
50 enrolled
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy
Phase 1 Completed
29 enrolled 11 charts
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Phase 1 Completed
28 enrolled
Haplo Peripheral Blood Sct In GVHD Prevention
Phase 1 Completed
25 enrolled
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
Phase 1 Completed
31 enrolled
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1 Completed
141 enrolled 37 charts
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase 1 Completed
54 enrolled 24 charts
CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
Phase 1 Completed
20 enrolled
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
Phase 1 Completed
95 enrolled
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Phase 1 Completed
22 enrolled
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
Phase 1 Completed
52 enrolled
STELLA
Phase 1 Completed
40 enrolled
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
Phase 1 Completed
30 enrolled
A Study of PD5K3 in Healthy Adult Volunteers
Phase 1 Completed
28 enrolled
CRAD001NUS175T
Phase 1 Completed
22 enrolled
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
Phase 1 Completed
17 enrolled 17 charts
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
Phase 1 Completed
10 enrolled
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Phase 1 Completed
18 enrolled 15 charts
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Phase 1 Completed
91 enrolled
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
Phase 1 Completed
19 enrolled
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Phase 1 Completed
29 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
35 enrolled
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Phase 1 Completed
16 enrolled 16 charts
ENCERT
Phase 1 Completed
8 enrolled
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Phase 1 Completed
143 enrolled
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Phase 1 Completed
50 enrolled 14 charts
Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)
Phase 1 Completed
6 enrolled
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Phase 1 Completed
14 enrolled
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Phase 1 Completed
24 enrolled
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
11 enrolled
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Phase 1 Completed
286 enrolled 26 charts
HPDSC
Phase 1 Completed
43 enrolled
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
Phase 1 Completed
6 enrolled
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
Phase 1 Completed
26 enrolled
Single and Multiple Ascending Dose Study With EP395
Phase 1 Completed
78 enrolled
Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Phase 1 Completed
9 enrolled
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
Phase 1 Completed
10 enrolled
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
Phase 1 Completed
10 enrolled
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
Phase 1 Completed
70 enrolled
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
Phase 1 Completed
44 enrolled
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Phase 1 Completed
69 enrolled
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
Phase 1 Completed
81 enrolled
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Phase 1 Completed
21 enrolled
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
Phase 1 Completed
80 enrolled
Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia
Phase 1 Completed
9 enrolled
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Phase 1 Completed
71 enrolled